In one paragraphArticle in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
Malgorzata StatkiewiczLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-2170-1909 Izabela RumienczykLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-2957-8952 Urszula PakulskaRyvu Therapeutics, 30-394 Krakow, Poland.
Maria KuleckaLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Jarosław CendrowskiLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-8579-7279 Magdalena Cubulska-LubakLaboratory of Preclinical Research, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Ewelina KaniugaLaboratory of Preclinical Research, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0002-2761-9685 Zuzanna Sandowska-MarkiewiczLaboratory of Preclinical Research, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Wioletta Slusarczyk-KacprzykDepartment of Medical Physics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-0150-7543 Krzysztof GorycaGenomics Core Facility, Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-1250-1008 Tymon RubelInstitute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, 00-661 Warsaw, Poland.ORCID 0000-0002-1342-414X Magdalena BakunMass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0001-8542-2234 Bianka SwiderskaMass Spectrometry Laboratory, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.ORCID 0000-0002-9373-4008 Kamila Kruczkowska-TarantowiczDepartment of Internal Medicine and Hematology, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.ORCID 0009-0000-8927-5227 Piotr RzepeckiDepartment of Internal Medicine and Hematology, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Jolanta KorsakDepartment of Clinical Transfusion Medicine, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Krystyna Kyc-WachowiakDepartment of Clinical Transfusion Medicine, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Anna PolakDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, 04-141 Warsaw, Poland.ORCID 0000-0001-8686-3429 Przemyslaw JuszczynskiDepartment of Experimental Hematology, Institute of Hematology and Transfusion Medicine, 04-141 Warsaw, Poland.ORCID 0000-0001-7215-0444 Milena MazanRyvu Therapeutics, 30-394 Krakow, Poland.
Tomasz RzymskiRyvu Therapeutics, 30-394 Krakow, Poland.
Jerzy OstrowskiLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-1363-3766 Michal MikulaLaboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.ORCID 0000-0003-3447-7328 Funding
National Science Centre 2018/30/E/NZ2/00801
6 · The paper itselfAbstract
Acute myeloid leukaemia (AML) is a therapeutically challenging malignancy driven by the self-renewal, quiescence, and therapy resistance of leukaemic stem cells (LSCs). CDK8, a kinase component of the Mediator complex, regulates oncogenic transcription, and the selective CDK8/CDK19 inhibitor RVU120 (Romaciclib) targets AML cells with CD34
Indexed as
Cell DifferentiationCyclin-Dependent Kinase 8Leukemia, Myeloid, AcuteAnimalsBromodomain Containing ProteinsCell Line, TumorDrug SynergismHumansMiceMultiomicsProtein Interaction MapsProtein Kinase InhibitorsProteinsProteomicsbromodomain and extra-terminal domain protein, humanBromodomain Containing ProteinsCDK8 protein, humanCyclin-Dependent Kinase 8Protein Kinase InhibitorsProteinsBET-CDK8 synergyCDK8 inhibitorchromatin remodellingleukaemic stem cellsprotein–protein interactome
Identifiers
PMID42587822
PMCPMC13465939
What OpenQuestion holds
Textmetadata
Read underepoch 390